Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients (NCT07116746)
A Phase 2, Multicenter, Open-label, Efficacy and Safety Study of AR882 and XOI Co-administration in Participants With Uncontrolled Gout Who Have Previously Failed Uricase Treatment
🩺 Plain-English Summary (8th-Grade Level)
This study will assess the effect of AR882 and XOI co-administration on sUA lowering as well as reducing tophus burden in the population that has failed uricase treatment (eg., pegloticase). Failed uricase treatment is defined as having an inherent intolerance, anaphylaxis, infusion reaction, antibody development, and/or at least one sUA level that rose to greater than 6 mg/dL while on therapy.
Who can join: Review the eligibility criteria below.
Location: Arthrosi Investigative Site (105) — Margate, Florida
Age range: 18 Years to 85 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (8 Sites)
- Arthrosi Investigative Site (105) — Margate, Florida
- Arthrosi Investigative Site (102) — Miami, Florida
- Arthrosi Investigative Site (109) — Tampa, Florida
- Arthrosi Investigative Site (106) — Jackson, Mississippi
- Arthrosi Investigative Site (108) — Charlotte, North Carolina
- Arthrosi Investigative Site (103) — Duncansville, Pennsylvania
- Arthrosi Investigative Site (104) — West Lake Hills, Texas
- Arthrosi Investigative Site (107) — Bellevue, Washington
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Gout
- Assessing the Role of the NLRP3 Inflammasome in Intercritical Gout — Beverly Hills, California
- Gout in the ED and Improving Research Participation — Birmingham, Alabama
- Dose Finding Study to Evaluate Safety and Efficacy of 3 Dosages of SAP 001. — Sacramento, California
- PK and Safety Evaluation Study of SAP-001 in Adult Subjects With Normal and Impaired Renal Function — Tampa, Florida
- Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301) — Birmingham, Alabama
Explore by condition: All Gout clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.